Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Decreases By 25.1%

InMed Pharmaceuticals Inc. (NASDAQ:INM) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 26,900 shares, a decrease of 25.1% from the February 13th total of 35,900 shares. Based on an average trading volume of 462,300 shares, the short-interest ratio is currently 0.1 days. Approximately 3.8% of the company’s shares are short sold.

InMed Pharmaceuticals Price Performance

INM stock opened at $2.82 on Friday. InMed Pharmaceuticals has a 52-week low of $2.41 and a 52-week high of $15.70. The company has a quick ratio of 2.44, a current ratio of 3.05 and a debt-to-equity ratio of 0.09. The stock has a market cap of $3.40 million, a price-to-earnings ratio of -0.21 and a beta of 0.18. The business has a fifty day moving average of $3.49 and a two-hundred day moving average of $4.47.

InMed Pharmaceuticals (NASDAQ:INM) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($3.64) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative return on equity of 90.74% and a negative net margin of 163.75%.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.